Scarica l'app Stockscreener
9.02
2.65%
-0.43
Dopo l'orario di chiusura:
9.02
Precedente Chiudi:
$9.45
Aprire:
$10.17
Volume 24 ore:
9,692
Relative Volume:
1.38
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-32.30%
1M Prestazione:
-0.76%
6M Prestazione:
+0.55%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.02
$10.29
Intervallo di 1 settimana:
$9.02
$14.80
Portata 52W:
$2.60
$16.75
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
Nome
Newamsterdam Pharma Company N V
Settore
Industria
Telefono
31 35 206 2971
Indirizzo
Gooimeer 2-35, Naarden
Confronta NAMSW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NAMSW | 9.02 | 0 | 0 | 0 | 0 | 0.00 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Newamsterdam Pharma Company N V Borsa (NAMSW) Ultime notizie
NewAmsterdam Pharma's (NAMS) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
NewAmsterdam Pharma target raised to $45 on strong trial data - Investing.com
Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online
NewAmsterdam Pharma target raised to $45 on strong trial data By Investing.com - Investing.com UK
NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times
NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com
Trend Tracker for (NAMSW) - Stock Traders Daily
Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times
RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com
GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St
When the Price of (NAMS) Talks, People Listen - Stock Traders Daily
Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World
William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World
(NAMSW) Proactive Strategies - Stock Traders Daily
What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga
Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat
NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan
abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times
Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia
NewAmsterdam Pharma to Restate Prior Financials - Investing.com India
Latest Company News - Investing.com UK
(NAMSW) Trading Report - Stock Traders Daily
NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat
NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN
Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily
Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha
NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat
Newamsterdam Pharma Company N V Azioni (NAMSW) Dati Finanziari
Non sono disponibili dati finanziari per Newamsterdam Pharma Company N V (NAMSW). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
3.56%
Capitalizzazione:
|
Volume (24 ore):